Car t-cell - OmicsDI

Show results for

Unknown (5576)
Genomics (1273)
Transcriptomics (959)
Other (75)
Proteomics (75)
Metabolomics (19)
Clinical (15)
Methylation profiling (15)
Models (12)
Genomic (1)

Organisms

Homo sapiens (828)
Mus musculus (329)
Aerococcus urinae NBRC 15544 = CCUG 36881 (53)
Rattus norvegicus (20)
Mucor circinelloides (4)
Drosophila melanogaster (4)
Saccharomyces cerevisiae (3)
Arabidopsis thaliana (3)
Macaca mulatta (3)
Mus sp. (2)
Sus scrofa (2)
Escherichia coli (2)
Mus musculus domesticus (2)
synthetic construct (2)
Mimosa pudica (1)
human gut metagenome (1)
Macaca nemestrina (1)
Thalassiosira pseudonana (1)
Rattus rattus (1)
Hordeum vulgare subsp. vulgare (1)
Bos taurus (1)
Caenorhabditis elegans (1)
Pseudomonas aeruginosa (1)
Gallus gallus (1)
Canis lupus familiaris (1)
Danio rerio (1)
Homo sapiens/Mus musculus xenograft (1)
Human immunodeficiency virus 1 (1)
other sequences (1)
synthetic virus (1)

Organisms

Homo sapiens (696)
Mus musculus (245)
Mus musculus domesticus (2)
Macaca mulatta (2)
Homo sapiens/Mus musculus xenograft (1)
Human immunodeficiency virus 1 (1)
synthetic construct (1)
Canis lupus familiaris (1)
Mus musculus musculus (1)
Danio rerio (1)

Repository

ENA (1150)
geo (908)
biostudies-arrayexpress (230)
pride (53)
EGA (33)
MetaboLights (19)
BioModels (12)
MassIVE (12)
iProX (8)
NODE (2)
dbGaP (1)
PanoramaPublic (1)

Tissue

T cell (25)
Cell culture (12)
Blood (10)
B cell (5)
Cell suspension culture (3)
Epithelial cell (3)
JURKAT cell (3)
Lung (2)
Monocyte (2)
T-lymphocyte (2)
Bone marrow CD45+ cells (1)
T cell and 293T (1)
B-cell lymphoma/leukemia 11B (1)
Blood cell (1)
Blood plasma (1)
Brain (1)
Extracellular vesicle (1)
Liver (1)
Macrophage (1)
Natural killer cell (1)
Neuroblastoma cell (1)
Neuron maturation (1)
Oligodendrocyte (1)
Permanent cell line cell (1)
Primary cell (1)
Spleen (1)
Whole body (1)

Disease

Lymphoma (4)
Acute leukemia (4)
Leukemia (3)
Colorectal Neoplasms (3)
Multiple myeloma (3)
Neuroblastoma (3)
Lymphoid leukemia (2)
Cancer (2)
Normal (2)
B-cell acute lymphoblastic leukemia (2)
Glioblastoma multiforme (1)
Non-Hodgkin lymphoma (1)
Chronic granulomatous disease (1)
Sham treated (1)
IRAK-4 Q293X mutation (1)
Leukemia (1)
Colorectal cancer, gastric cancer, liver cancer, pancreatic cancer, esophageal adenocarcinoma, esophagogastric junction cancer, etc (1)
Acute lymphoblastic leukaemia [ALL] (1)
Advanced colorectal cancer (1)
Carcinoma, Squamous Cell (1)
Neuroendocrine Tumors (1)
Pancreatic Neoplasms (1)
Neoplasm Metastasis (1)
Stomach Neoplasms (1)
Lung Neoplasms (1)
Carcinoma (1)
Neoplasms (1)
Acute lymphocytic leukemia (1)
Alveolar rhabdomyosarcoma (1)
B-lymphoblastic leukemia/lymphoma (1)

Technology Type

Mass Spectrometry (53)
Bottom-up proteomics (22)
Shotgun proteomics (13)
Mass spectrometry (10)
Data-dependent acquisition (10)
Mass spectrometry assay (7)
Affinity purification coupled with mass spectrometry proteomics (7)
Data-independent acquisition (6)
SWATH MS (5)
Illumina HiSeq 2000 (2)
NMR spectroscopy (2)
ILLUMINA, Illumina HiSeq 2000 (1)
Chemical cross-linking coupled with mass spectrometry proteomics (1)
Gel-based experiment (1)
Immunopeptidomics (1)

Instrument Platform

Illumina NovaSeq 6000 (26)
NextSeq 500 (4)
Illumina HiSeq 2000 (3)
Orbitrap Eclipse (3)
Orbitrap Fusion Lumos (3)
Illumina NovaSeq X (2)
NextSeq 550 (2)
Illumina HiSeq 2500 (2)
Q Exactive (2)
Novogene in-house automated library preparation system (1)
Novogene automated library prep system (1)
Qiagen RNA extraction kit (1)
BD FACS ARIA III analyser (1)
CytoFLEX SRT Benchtop Cell Sorter (1)
Sony SH800S Cell Sorter (1)
10x Chromium with a target of 5,000 cells. Chromium Single Cell 3’ Library & Gel Bead Kit v2 (1)
10X Genomics reagent kit (1)
10x Genomics Chromium (1)
BD FACSAria III cell sorter (1)
G2505A DNA microarray scanner [Agilent] (1)
Scanning hardware (1)
NA (1)
Illumina HiSeq 1000 (1)
Illumina HiSeq 4000 (1)
LTQ Orbitrap Velos (1)
Orbitrap Fusion (1)
Q Exactive HF (1)
Q Exactive Plus (1)
QExactive HF (1)
TimsTOF Pro 2 (1)

Publication Date

2026 (273)
2025 (219)
2024 (167)
2023 (130)
2021 (85)
2022 (85)
2020 (36)
2014 (29)
2019 (27)
2012 (27)
2013 (26)
2011 (26)
2015 (21)
2016 (19)
2018 (17)
2010 (17)
2008 (11)
2017 (9)
2007 (7)
2009 (6)
2006 (2)
2004 (2)
2005 (1)

CHEBI ID

CHEBI:144829 (5)
CHEBI:22469 (4)
CHEBI:17580 (4)
CHEBI:15366 (3)
CHEBI:67251 (3)
CHEBI:80945 (2)
CHEBI:35986 (2)
CHEBI:32325 (2)
CHEBI:16188 (2)
CHEBI:87393 (2)
CHEBI:17700 (2)
CHEBI:87430 (2)
CHEBI:50025 (2)
CHEBI:87432 (2)
CHEBI:43003 (2)
CHEBI:15688 (2)
CHEBI:28768 (2)
CHEBI:17790 (2)
CHEBI:7563 (2)
CHEBI:17447 (2)
CHEBI:30751 (2)
CHEBI:50129 (2)
CHEBI:17987 (2)
CHEBI:17053 (2)
CHEBI:15354 (2)
CHEBI:18009 (2)
CHEBI:25017 (2)
CHEBI:16015 (2)
CHEBI:18050 (2)
CHEBI:16737 (2)

Metabolite Name

2-Undecanone (3)
Inosine (3)
Ureidopropionate (2)
Alpha-Terpineol (2)
Formate (2)
Methanol (2)
Acetate (2)
Methyl octanoate (2)
2'-Deoxyadenosine (2)
2,4-Di-tert-butylphenol (2)
Taurocholic acid (2)
P-Cymene (2)
Beta-Ionone (2)
Ornithine (2)
L-Cystine (2)
Lumichrome (2)
Urea (2)
Uracil (2)
Nicotinamide (2)
Lysine (2)
L-Alanine (2)
Putrescine (2)
Allantoin (2)
Taurine (2)
Linalool (2)
Threonine (2)
Adenine (2)
Guanosine (2)
Lactate (2)
AMP (2)

First Public Date

2026 (300)
2025 (218)
2024 (186)
2023 (148)
2021 (101)
2022 (94)
2020 (41)
2019 (26)
2018 (21)
2017 (9)
2014 (3)
2015 (2)
2016 (1)

Modelling Approach

Ordinary differential equation model (11)
Agent-based model (1)

Study status

Recruiting (9)
Not provided (2)
Completed (2)
Not yet recruiting (2)

Lab affiliation

Instituto de Investigaciones Sanitarias de Santiago de Compostela (3)
Brown University, MCB Department (2)
Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA (2)
Institute for Immunology, Tsinghua University; Beijing, China (2)
Moffitt Cancer Center (2)
Roswell Park Cancer Center Buffalo, NY, USA (2)
Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China University of Science and Technology of China, Hefei, Anhui 230026, P. R. China Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China (1)
Assistant Professor, Pediatrics-Heme/Onc and Bone Marrow Transplantation (1)
Associate Professor, Department of Laboratory Mediciene, UCSF (1)
Bavarian Center for Biomolecular Mass Spectrometry at Klinikum rechts der Isar, Technical University of Munich (1)
Berlin Institute of Health (BIH) at Charité – Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Experimental Immunotherapy (1)
Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), 138648 Singapore, Singapore. Department of Pharmacy and Pharmaceutical Sciences, National University of Singapore, 117543, Singapore, Singapore. (1)
Brown University MCB Department (1)
Chief Scientific Officer oNKo-innate Pty Ltd Laboratory Head, Huntington Laboratory Monash Biomedicine Discovery Institute Monash University Victoria Australia (1)
Department of Biochemistry and Immunology, Ribeirão PretoMedical School, University of São Paulo, Ribeirão Preto, São Paulo, 14049-900, Brazil. (1)
Department of Laboratory Medicine and Pathology, Mayo Clinic, USA (1)
Department of Microbiology & Immunology, 2the Cancer Center, Medical College of Wisconsin Department of Medicine, Medical College of Wisconsin, Milwaukee, WI (1)
Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI, 02903 (1)
Director, Center for Cell Engineering, Sloan Kettering Institute (1)
Division of Pediatric Hematology and Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland (1)
Gladstone Institutes, San Francisco, CA, USA Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA, USA Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA (1)
Huazhong University of Science and Technology (1)
Immunology Department, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland (1)
Institute of Biochemistry II, Faculty of Medicine, Goethe University, Frankfurt am Main, Germany Frankfurt Cancer Institute, Frankfurt am Main, Germany Cardio-Pulmonary Institute, Frankfurt am Main, Germany (1)
Institute of Mechanobiology and Medical Engineering School of Life Sciences and Biotechnology Shanghai Jiao Tong University Shanghai China (1)
Ist. G. Gaslini - Core Facilities - Proteomica Clinica (1)
Laboratorio Core Facilities Gaslini Children's Hospital (1)
Mass Spectrometry & Proteomics Core Facility (MSPCF) Institute for Research in Biomedicine (IRB Barcelona) Barcelona Institute of Science and Technology (BIST) C/ Baldiri Reixac, 10-12 08028 Barcelona - Spain (1)
National Institute of Standards and Technology Institute for Bioscience and Biotechnology Research (1)
Neurosurgeon & Senior Scientist Developmental and Stem Cell Biology, The Hospital for Sick Children, Canada (1)

Keyword

Immunotherapy (3)
CAR-T (2)
CAR T Cell (2)
Autologous (2)
HLA-A2 (2)
Pancreatic (2)
PANC (2)
CEA (2)
CAR-T cell (1)
Minimal residue disease (1)
CAR T Cell Therapy (1)
Leukapheresis (1)
Pancreas Cancer (1)
Human Epidermal Growth Factor Receptor 2 (1)
Salivary Gland (1)
Breast (1)
CAR T-cells (1)
Patient-Derived Organoids (1)
CEA-positive advanced malignant solid tumors (1)
Next Generation Sequencing (1)
Carcinoembryonic antigen (1)
T cell (1)
Carcinoembryonic Antigen (1)
Solid Tumors Expressing CEA (1)
Liver metastasis (1)
Lung (1)
Esophageal (1)
Immunomodulating Agents (1)
T Cell (1)
Mesothelin (1)

IsPrivate

False (12)

Submitter Keywords

Immuno-oncology (8)

Classification

viruses (1)

Modification

4x(15)N labeled L-arginine (1)

Study type

Transcription profiling by array (144)
RNA-seq of coding RNA (28)
RNA-seq of coding RNA from single cells (17)
Interventional (12)
Comparative genomic hybridization by array (11)
ChIP-seq (7)
Methylation profiling by array (7)
Unknown experiment type (3)
Observational (3)
ChIP-chip by tiling array (2)
Human - One-color microarray (2)
Other (2)
RNA-seq of non coding RNA (2)
RNA-seq of non coding RNA from single cells (1)
Genotyping by array (1)
Transcription profiling by RT-PCR (1)
DNA-seq (1)
RNA-seq of total RNA (1)

Release Date

2023 (908)
2025 (891)
2022 (846)
2021 (757)
2024 (684)
2020 (490)
2019 (289)
2018 (227)
2026 (135)
2017 (133)
2016 (103)
2015 (91)
2014 (55)
2013 (47)
2012 (43)
2011 (37)
2010 (31)
2008 (14)
2009 (10)
2007 (8)
2006 (3)
2004 (2)
2005 (1)
2000 (1)

Location

China (6)
United States (5)
Norway (1)
Germany (1)
United Kingdom (1)

Previous page
1 / 802
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 802
Next page

Sort by:

Relevance

Page size

IFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma (CAR-T Metabolites)

Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...

2026-05-31 | MTBLS14640 | MetaboLights

IFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma

2026-05-31 | MTBLS14634 | MetaboLights

IFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma (Glucose Tracer)

2026-05-31 | MTBLS14641 | MetaboLights

A polyamine-centric blood-based metabolite panel predictive of poor response to CAR T-cell therapy in large B cell lymphoma

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (r/r) large B-cell lymphoma (LBCL) results in durable response in only a subset of patients. MYC overexpression in LBCL tumors is associated with poor response to treatment. We tested whether a MYC-driven polyamin...

2022-10-31 | MTBLS5381 | MetaboLights

Nanoinducers-mediated Mitochondria-Selective Degradation Enhance T Cell Immunotherapy Against Multiple Cancers

Cancer immunotherapy utilizing cytotoxic T lymphocytes (CTLs) has demonstrated significant promise in clinical applications, but cancer immunosuppressive mechanisms hamper further progress in T cell immunotherapy. Here we show a correlation between cancer cell mitochondria content and their resis...

2025-03-13 | MTBLS12284 | MetaboLights

Ferritin aggregation: A neotype and universal engager for CAR T cell avidity engineering against diverse refractory leukemias

Introduction: Primary liver cancer remains the third leading cause of global cancer-related mortality, with hepatocellular carcinoma (HCC) constituting the predominant histological subtype. The development of malignant ascites in advanced HCC patients signifies metastatic progression and portends...

2025-12-24 | MTBLS13569 | MetaboLights

Targeted scRNA-seq and AbSeq of human CAR-T cell infusion product from 28 cancer patients

Immunotherapy using CD19-directed chimeric antigen receptor (CAR)-T cells has shown excellent results for treatment of B-cell leukaemia and lymphoma. To produce CAR-T cells, the patient’s own T cells are isolated from the blood and modified in a laboratory with a genetic vector to express a tumor an...

ORGANISM(S): Homo sapiens

2023-07-24 | E-MTAB-12407 | biostudies-arrayexpress

Targeting secreted MDK-mediated tryptophan/kynurenine metabolism enhances DLL3 CAR T therapy for SCLC

Small cell lung cancer (SCLC) exhibits profound immunometabolic suppression that impairs antigen presentation and constrains immunotherapy efficacy. Through integrated multi-omics analyses of primary human SCLC tumors, we identified midkine (MDK) as a dominant tumor-secreted driver of immune evas...

2026-03-23 | MTBLS14116 | MetaboLights

Generation of clinical grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of B-cell malignancies

Long-lived, self-renewing, multipotent T memory stem cells (TSCM) can trigger profound and sustained tumor regression but their rareness poses a major hurdle to their clinical application. Presently, clinically compliant procedures to generate relevant numbers of this T cell population are undefined...

ORGANISM(S): Homo sapiens

2016-06-29 | E-GEOD-68003 | biostudies-arrayexpress

CAR-adapted PIK3CD base editing enhances T cell anti-tumor potency

Insufficient functional T cell persistence impedes therapeutic success of chimeric antigen receptor (“CAR”) therapies. Here, we performed a CAR-adapted base editing screen of PIK3CD, a key regulator of T cell function, metabolism, and fate. We identified point mutations that beneficially modulate CA...

ORGANISM(S): Homo sapiens

2025-11-06 | E-MTAB-15749 | biostudies-arrayexpress

Previous page
1 / 802
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 802
Next page

Sort by:

Relevance

Page size

8020 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

First Public Date

Modelling Approach

Study status

Lab affiliation

Tags

Keyword

IsPrivate

Submitter Keywords

Classification

Modification

Study type

Release Date

Location

OmicsDI is part of the ELIXIR infrastructure

Tweets